Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Relay Therapeutics, Inc.NASDAQ: RLAY
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables growth accelerates
Q2 FY2026 accounts payables of $3.67M (cash outflow) rose 284.7% year over year, ahead of the -374.8% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 74.5% of revenue in FY2025, up 74.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +284.7% holds above the trailing-twelve-month pace of -374.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (11.44M) USD
- Year-over-year change
- —
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.44M) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (2.39M) | -220.4% |
| FY2022 | 2022-12-31 | 1.99M | +113.9% |
| FY2021 | 2021-12-31 | 930K | — |
Accounts Payables vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 accounts payables of $7.04M is the 3rd largest of the 11 companies compared; the peer median is $2.11M.
- Its year-over-year change of -374.8% is the 9th highest of 10, against a peer median of +27.9%.
- Accounts payables amounts to 68.0% of revenue for RLAY, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $30.93M | +14.3% | +9.4% | — | |
| LTM Aug 2026 | $25.05M | +537.3% | — | 3.6% | |
| LTM Jun 2026 | $7.04M | -374.8% | — | 68.0% | |
| LTM Mar 2026 | $4.37M | +2029.8% | -8.6% | — | |
| LTM Mar 2026 | $3.89M | -608.8% | +124.3% | 23.2% | |
| LTM Jun 2026 | $3.39M | +1670.4% | — | 3.2% | |
| LTM Mar 2026 | $3.02M | -73.7% | +13.1% | 1.3% | |
| LTM Mar 2026 | $1.2M | — | — | — | |
| LTM Sep 2026 | $798K | +27.9% | -8.8% | — | |
| LTM Mar 2026 | $448K | +36.6% | +70.0% | — | |
| LTM Sep 2026 | $365K | -82.6% | — | — | |
| Peer median (excluding RLAY) | $2.11M | +27.9% | +11.2% | 3.4% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.45M | 56.14M | 86.03M | 94.14M | 62.42M |
| Change in Working Capital | 97.34M | 11.25M | (32.46M) | 14.62M | (23.31M) |
| Accounts Receivables | 77.79M | 97K | 5.22M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 930K | 1.99M | (2.39M) | 0 | (11.44M) |
| Other Working Capital | 18.62M | 9.16M | (35.28M) | 14.62M | (11.87M) |
| Other Non-Cash Items | 139.74M | (10.5M) | (17.19M) | (25.62M) | (1.65M) |
| Operating Cash Flow | (74.41M) | (229.49M) | (300.32M) | (249.11M) | (235.46M) |
| Capital Expenditures | (3.47M) | (9.06M) | (4.13M) | (2.02M) | (410K) |
| Acquisitions (Net) | (25.3M) | 179.68M | 0 | 0 | 0 |
| Purchases of Investments | (980.67M) | (535.42M) | (385.54M) | (650.63M) | (122.97M) |
| Sales of Investments | 529.92M | 355.74M | 647.3M | 611.56M | 316.18M |
| Other Investing Activities | 0 | (179.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (479.51M) | (188.75M) | 257.63M | (41.08M) | 192.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 382.21M | 284.74M | 30.28M | 265.89M | 1.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.88M | 5.17M | 4.47M | 4.26M | 0 |
| Financing Cash Flow | 388.09M | 289.91M | 34.75M | 270.15M | 1.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (165.83M) | (128.33M) | (7.93M) | (20.04M) | (41.05M) |
| Free Cash Flow | (77.88M) | (238.55M) | (304.44M) | (251.13M) | (235.87M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.